daaimon

daaimon is an independent research company focusing on healthcare and consumer sectors across developed and emerging markets. We produce insightful research which challenges conventional thinking. In particular, we look for new ideas by testing consensus forecasts and markets expectations.

Daiichi Sankyo (4568 JP) – Were We Too Early in Oct 2024?

What Do Multinational Pharma Companies Know that Equity Investors Don’t?

Understanding Drug Imbursement Price Cuts in China

Healthcare Equity Analyst - Emerging & Dev Markets, daaimon

Avien Pillay

Healthcare Equity Analyst - Emerging & Dev Markets

Independent Insight Provider

Equity Bottom-Up

<ul>
<li>Cancer is the most common cause of death in Japan, and at 282.9 cases per 100 000 people, it ranks at the upper end of the global recorded range.</li>
<li>In 2020, Daiichi Sankyo embarked on transforming to a leading oncology specialist in terms of new drug development.</li>
<li>Daiichi Sankyo’s ADC pipeline comprises of six higher level drugs with a number of indications (sub-categories). This pipeline is part of a universe of 2499 oncology drugs in development.</li>
</ul>


Cancer is the most common cause of death in Japan, and at 282.9 cases per 100 000 people, it ranks at the upper end of the global recorded range.
In 2020, Daiichi Sankyo embarked on transforming to a leading oncology specialist in terms of new drug development.
Daiichi Sankyo’s ADC pipeline comprises of six higher level drugs with a number of indications (sub-categories). This pipeline is part of a universe of 2499 oncology drugs in development.


第一三共（4568 JP） – がん領域への注力は魅力的だが、より良いエントリーポイントを探している